Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma $MBIO $FBIO https://bit.ly/40BOOzp
关于我们
Mustang Bio, Inc. (“Mustang”) is a clinical-stage bio-pharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.
- 网站
-
https://www.mustangbio.com/
Mustang Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Worcester，Massachusetts
- 类型
- 上市公司
地点
-
主要
获取路线
377 Plantation St
US，Massachusetts，Worcester，01605
Mustang Bio员工
动态
-
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy $MBIO $FBIO https://t.co/gMMZkCHIg7
-
Mustang Bio announces its expansion into #autoimmunediseases with MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the fourth quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more here:?https://bit.ly/4azqUGS
-
Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: https://bit.ly/3Vdj7Kk
-
Phase 1 clinical data were published in @NatureMedicine that demonstrated the promising safety and clinical activity of Mustang Bio’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO Learn more here:??https://bit.ly/3TeNAVQ